Analysis of the metabolic syndrome improvement with the orexin receptor antagonist

Not Applicable

• Conditions: Metabolic syndrome with insomnia

• Registration Number: JPRN-UMIN000027445
• Lead Sponsor: Kochi University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-06-01
• Study Completion: 2020-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 0

Inclusion Criteria

Not provided

Exclusion Criteria

The patients appeared harmful effect of suvorexant The patients prescribed with CYP3A inhibitory drugs

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
We will evaluate whether the patients fill the criteria of MS 6 months after suvorexant treatment. MS criteria is satisfied with abdominal circumference is higher than 85cm in male and 90cm in female, and with higher than two items in follows: (1) Dyslipidemia: triglyceride is higher than 150mg/dl and/or HDL cholesterol is lower than 40mg/dl. (2) Hypertension: systolic blood pressure is higher than 130mmHg and/or diastolic blood pressure is higher than 85mmHg. (3) Impaired glucose tolerance: fasting blood glucose is higher than 110mg/dl.